Literature DB >> 30941989

PI3K/AKT pathway genetic alterations and dysregulation of expression in bladder cancer.

Stefanos Kachrilas1, Athanasios Dellis, Athanasios Papatsoris, Socratis Avgeris, Dimitra Anastasiou, Ariana Gavriil, Maria Horti, Sofia Tseleni Balafouta, Konstantinos Livadas, Dimitrios Stravopodis, Gerassimos Alivizatos, Gerassimos Voutsinas, Charalambos Deliveliotis.   

Abstract

PURPOSE: To examine the involvement of specific components of the PI3K/AKT pathway in urinary bladder cancer development.
METHODS: Samples from 65 tumors and 13 normal bladder tissues were collected. Genomic DNA isolation from snap-frozen and paraffin-embedded laser-microdissected tissues was followed by Sanger sequencing, whereas total RNA was purified for use in RT-PCR analyses. Immunohistochemistry was carried out on sections of paraffin-embedded biopsy material.
RESULTS: Three pathogenic mutations (two missense and one frameshift) were identified in exon 20 of PIK3CA {c.3140A>G (p.His1047Arg), c.[3172A>T(;)3174C>T] (p.lle1058Phe), c.3203dupA (p.Asn1068Lysfs*5)} after laser capture microdissection, whereas PTEN mRNA expression was found to be downregulated in bladder cancer tissues compared to normal bladder urothelium. Upregulation of cytoplasmic and nuclear p-AKT expression was detected in low grade tumors, whereas in infiltrating carcinomas p-AKT was shown to be downregulated and confined to the cytoplasm. PTEN expression was weak and mainly cytoplasmic in superficial tumors, but stronger and nuclear in the infiltrating tumors.
CONCLUSIONS: PI3K/AKT pathway activation is crucial for bladder cancer initiation and progression. In this context, PIK3CA, p-AKT and nuclear PTEN could be used along with other biomarkers for prognosis and selection of appropriate therapy in the clinical management of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30941989

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  8 in total

1.  Loss of polarity protein Par3, via transcription factor Snail, promotes bladder cancer metastasis.

Authors:  Shenyi Wang; Jinming Cai; Si Zhang; Mingwei Dong; Li Zhang; Yingying Xu; Bing Shen; She Chen
Journal:  Cancer Sci       Date:  2021-05-01       Impact factor: 6.716

2.  lncRNA ZEB2-AS1 Aggravates Progression of Non-Small Cell Lung Carcinoma via Suppressing PTEN Level.

Authors:  Xiao Chen; Kangwu Wang
Journal:  Med Sci Monit       Date:  2019-11-07

3.  The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients.

Authors:  Xinhui Fu; Hanjie Lin; Xinjuan Fan; Yaxi Zhu; Chao Wang; Zhiting Chen; Xiaoli Tan; Jinglin Huang; Yacheng Cai; Yan Huang
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

4.  Expression and prognostic value of SULT1A2 in bladder cancer.

Authors:  Yinghui Chao; Qifeng Ou; Jin Shang
Journal:  Exp Ther Med       Date:  2021-05-19       Impact factor: 2.447

5.  Anticancer Activity of Erianin: Cancer-Specific Target Prediction Based on Network Pharmacology.

Authors:  Lili Yan; Zhen Zhang; Yanfen Liu; Shuyi Ren; Zhiyu Zhu; Lu Wei; Jiao Feng; Ting Duan; Xueni Sun; Tian Xie; Xinbing Sui
Journal:  Front Mol Biosci       Date:  2022-03-17

6.  Artificial Intelligence Meets Whole Slide Images: Deep Learning Model Shapes an Immune-Hot Tumor and Guides Precision Therapy in Bladder Cancer.

Authors:  Yiheng Jiang; Shengbo Huang; Xinqing Zhu; Liang Cheng; Wenlong Liu; Qiwei Chen; Deyong Yang
Journal:  J Oncol       Date:  2022-09-19       Impact factor: 4.501

7.  Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.

Authors:  Jia Lv; Yongze Zhu; Alin Ji; Qi Zhang; Guodong Liao
Journal:  Biosci Rep       Date:  2020-04-30       Impact factor: 3.840

Review 8.  Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy.

Authors:  Jianya Huan; Petros Grivas; Jasmine Birch; Donna E Hansel
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.